Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Huttunen

Showing results (51-60 of 157) with videos related to

Pageof 16
Sort By:
International Journal of Pharmaceutics|October 15, 2019
L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs)Johanna Huttunen, Mikko Gynther, Kati-Sisko Vellonen, et al.
Chemico-Biological Interactions|December 9, 2017
Biocompatible sulfenamide and sulfonamide derivatives of metformin can exert beneficial effects on plasma haemostasisMagdalena Markowicz-Piasecka, Kristiina M Huttunen, Elżbieta Mikiciuk-Olasik, et al.
Archives of General Psychiatry|January 22, 1998
The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling studyT D Cannon, J Kaprio, J Lönnqvist, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 1, 2017
L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugsElena Puris, Mikko Gynther, Johanna Huttunen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 10, 2019
L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain deliveryElena Puris, Mikko Gynther, Johanna Huttunen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 5, 2013
Convenient microwave-assisted synthesis of lipophilic sulfenamide prodrugs of metforminKristiina M Huttunen, Jukka Leppänen, Krista Laine, et al.
Pharmaceutics|June 24, 2022
Increased/Targeted Brain (Pro)Drug Delivery via Utilization of Solute Carriers (SLCs)Johanna Huttunen, Santosh Kumar Adla, Magdalena Markowicz-Piasecka, et al.
International Journal of Pharmaceutics|June 30, 2020
L-type amino acid transporter 1 (LAT1)-utilizing efflux transporter inhibitors can improve the brain uptake and apoptosis-inducing effects of vinblastine in cancer cellsAhmed Montaser, Magdalena Markowicz-Piasecka, Joanna Sikora, et al.
Journal of Pharmaceutical and Biomedical Analysis|June 2, 2009
Determination of metformin and its prodrugs in human and rat blood by hydrophilic interaction liquid chromatographyKristiina M Huttunen, Jarkko Rautio, Jukka Leppänen, et al.
Chemico-Biological Interactions|December 26, 2021
Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cellsMagdalena Markowicz-Piasecka, Johanna Huttunen, Agnieszka Zajda, et al.
Pageof 16

Showing results (51-60 of 157) with videos related to

Sort By:
Pageof 16
International Journal of Pharmaceutics|October 15, 2019
L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs)Johanna Huttunen, Mikko Gynther, Kati-Sisko Vellonen, et al.
Chemico-Biological Interactions|December 9, 2017
Biocompatible sulfenamide and sulfonamide derivatives of metformin can exert beneficial effects on plasma haemostasisMagdalena Markowicz-Piasecka, Kristiina M Huttunen, Elżbieta Mikiciuk-Olasik, et al.
Archives of General Psychiatry|January 22, 1998
The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling studyT D Cannon, J Kaprio, J Lönnqvist, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 1, 2017
L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugsElena Puris, Mikko Gynther, Johanna Huttunen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 10, 2019
L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain deliveryElena Puris, Mikko Gynther, Johanna Huttunen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 5, 2013
Convenient microwave-assisted synthesis of lipophilic sulfenamide prodrugs of metforminKristiina M Huttunen, Jukka Leppänen, Krista Laine, et al.
Pharmaceutics|June 24, 2022
Increased/Targeted Brain (Pro)Drug Delivery via Utilization of Solute Carriers (SLCs)Johanna Huttunen, Santosh Kumar Adla, Magdalena Markowicz-Piasecka, et al.
International Journal of Pharmaceutics|June 30, 2020
L-type amino acid transporter 1 (LAT1)-utilizing efflux transporter inhibitors can improve the brain uptake and apoptosis-inducing effects of vinblastine in cancer cellsAhmed Montaser, Magdalena Markowicz-Piasecka, Joanna Sikora, et al.
Journal of Pharmaceutical and Biomedical Analysis|June 2, 2009
Determination of metformin and its prodrugs in human and rat blood by hydrophilic interaction liquid chromatographyKristiina M Huttunen, Jarkko Rautio, Jukka Leppänen, et al.
Chemico-Biological Interactions|December 26, 2021
Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cellsMagdalena Markowicz-Piasecka, Johanna Huttunen, Agnieszka Zajda, et al.
Pageof 16